Business
Inspira™ Announces the Appointment of Tal Parnes as the New Chairman of the Board, Bringing Vast Experience in the Medical Technology and Pharmaceutical Sectors
RA'ANANA, Israel, Jan. 21, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in
About this update from Qtrex Quantum Ltd.
[{"type":"text","content":"RA'ANANA, Israel, Jan. 21, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (\"Inspira\" or the \"Company\"), a leader in life-support technology innovation, has announced the appointment of Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025.\n \n\n \nMr. Parnes brings a wealth of experience and expertise to his new role at Inspira. With a distinguished career spanning over three decades in the technology sector, with a special focus in the medical technology and pharmaceutical industries, Mr. Parnes has consistently demonstrated exceptional leadership and strategic vision.\nAs a serial entrepreneur, Parnes has demonstrated his ability to drive innovation and growth across various high-tech sectors, including medical technology, communications and defense. Mr. Parnes is familiar with the Company and its technology, having served as an independent director of the Company since July 2021.\nMr. Parnes is a veteran executive in the medical technology industry. He co-founded and is the former chief executive officer and president at Zuta-Core Ltd. and HQL Pharmaceuticals Ltd. Mr. Parnes also served as chief operating officer at Silynx Communications Inc. as a vice president of operations at Wavion Inc. and Atrica Ltd. He also served as chief financial officer and director of business development of Printlife Ltd.\nThe appointment of Mr. Parnes as chairman of the board of directors will enhance the Company's leadership. Mr. Parnes' unwavering commitment to integrating his vast knowledge of emerging technologies and market trends will be invaluable. Mr. Parnes' leadership will not only refine the Company's strategic vision but also bolster the Company's competitive advantage in the market, positioning the Company for sustainable success in the future. The Company is eager to harness Mr. Parnes' insights and experience as the Company reaches new heights.\nThe Company would like to thank Prof. Benad Goldwasser, MD, for his leadership role as chairman of the board of directors since 2021. The Company extends its gratitude for his numerous activities and contributions to the Company, spanning business, medical, and administrative aspects. Prof. Goldwasser provided invaluable support during the Company's Nasdaq Capital Market listing and leveraged his extensive ne...